Crossmark

488 Phase 1 trial of first-in-class anti-CD96 monoclonal antibody inhibitor, GSK6097608, monotherapy and combination with anti–PD-1 monoclonal antibody, dostarlimab, in advanced solid tumors

Crossref DOI link: https://doi.org/10.1136/jitc-2021-SITC2021.488

Published Online: 2021-11-10

Published Print: 2021-11

Update policy: https://doi.org/10.1136/crossmarkpolicy

Authors

Hamid, Omid

Baxter, Dawn

Easton, Rachael

Siu, Lilian
Clinical Trials ^BETA

Clinical trials referenced in this document:

nct04446351 at ClinicalTrials.gov

Documents that mention this clinical trial

488 Phase 1 trial of first-in-class anti-CD96 monoclonal antibody inhibitor, GSK6097608, monotherapy and combination with anti–PD-1 monoclonal antibody, dostarlimab, in advanced solid tumors
https://doi.org/10.1136/jitc-2021-sitc2021.488

nct04446351 at ClinicalTrials.gov

Documents that mention this clinical trial

488 Phase 1 trial of first-in-class anti-CD96 monoclonal antibody inhibitor, GSK6097608, monotherapy and combination with anti–PD-1 monoclonal antibody, dostarlimab, in advanced solid tumors
https://doi.org/10.1136/jitc-2021-sitc2021.488

nct04446351 at ClinicalTrials.gov

Documents that mention this clinical trial

488 Phase 1 trial of first-in-class anti-CD96 monoclonal antibody inhibitor, GSK6097608, monotherapy and combination with anti–PD-1 monoclonal antibody, dostarlimab, in advanced solid tumors
https://doi.org/10.1136/jitc-2021-sitc2021.488

Document is current

Any future updates will be listed below